#Norway #Oslo #Radspherin #Ovarian Cancer #Oncoinvent

Oncoinvent ASA's Half-Yearly Report

Oncoinvent ASA has recently released its half-yearly report highlighting its significant strides in the ongoing Phase 2 clinical trial for ovarian cancer treatment. The company remains committed to advancing their research programs while maintaining a robust financial discipline.

Key Highlights of the First Half of 2025

• - Clinical Trials: The results show continued progress in the Phase 2 trial targeting ovarian cancer. Key achievements include positive final outcomes from the Phase 1/2a trial in colorectal cancer, positive interim data after 18 months for ovarian cancer patients, and a successful safety lead-in phase that transitioned to a randomized section of the Phase 2 trial.
• - Regulatory Approvals: The company has received regulatory clearances for additional trial sites, anticipated to onboard before the end of 2025, enhancing recruitment and reach for their research efforts.
• - Corporate Performance: Operating expenses have seen a notable reduction of 28% compared to the previous year, demonstrating effective cost management strategies. Additionally, Oncoinvent announced a merger with BerGenBio and a guaranteed rights issue amounting to NOKm 130, to bolster its financial and operational capabilities.

Notable Presentations

CEO Øystein Soug and CFO Tore Kvam will present these results in a webcast on August 27, 2025, at 08:00 CEST. The presentation will be conducted in English with an accompanying Q&A session, available for viewing post-presentation on the company’s website.

About Oncoinvent

Oncoinvent is a biotechnology company focused on developing innovative radiopharmaceutical therapies for cancer treatment. Their lead candidate, Radspherin®, employs radium-224 to target micro-metastases following surgical procedures, maximizing therapy effectiveness while minimizing complexity. The investigational drug is currently being evaluated for safety and effectiveness in clinical trials for both ovarian and colorectal cancers throughout the US, UK, and Europe.

Clinical Developments

The clinical efficacy data thus far have been promising, with no severe safety issues reported during the trials. Radspherin® works by utilizing alpha-particles emitted from radium-224 to treat carcinomatosis, specifically when tumors have spread within body cavities. It is administered intraperitoneally after the surgical removal of existing tumors.

Forward-Looking Statements

It is essential to note that statements made within this release are considered forward-looking and do not guarantee outcomes. Oncoinvent manages all associated uncertainties and risks as they navigate further research and study conclusions.

For more detailed information, please reach out to:

• - Øystein Soug, CEO (Email: [email protected])
• - Tore Kvam, CFO (Email: [email protected])

These interactions reflect Oncoinvent's commitment to communicating its progress and fostering transparency with stakeholders as they continue to explore frontier technologies in cancer treatment and management.